Tagged with China

China The company sold 551 million shares in the latest IPO on the Hong Kong Exchange and plans to invest half of its earnings in R&D. Hong Kong is now the second largest biotech funding hub in the world.    Hansoh Pharmaceutical, one of China’s fastest-growing pharma companies, raised a billion…

Hong Kong With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019 conference in Philadelphia, the HKEX’s Michael Chan outlined some of the successes that the Hong Kong exchange has already seen and the exciting and diverse future listings in the pipeline.  …

China China is a hot topic in Big Pharma investor updates these days. The world’s second-largest pharmaceutical market boasts sales growth that continuously surpasses that of the US and other developed regions. However, with the rollout of the “4+7” procurement scheme slashing drug prices, industry insiders are predicting a more turbulent…

Biotech Hong Kong is now the world’s second largest funding hub for biotech according to Hong Kong Chief Executive Carrie Lam. During her speech at the 2nd HKEx Biotech Summit on May 29, Lam stated that innovation and technology have become a clear priority in government policy.   We have invested…

China On May 30th, and with much fanfare, Pfizer Upjohn officially inaugurated its global headquarters in the heart of Shanghai, China. Following a global re-organization mid-2018, Pfizer now operates three business units, namely Innovative Medicines (including biosimilars and a new hospital business unit dealing with anti-infectives and sterile injectables), Consumer Healthcare,…

China Carsten Lu of Chinese biotech Adlai Nortye outlines his strategy for navigating a crowded immuno-oncology field in China, his partnership strategy, and the firm’s early move to establish a footprint in the USA.   The Chinese biotech industry itself is already moving at supersonic speeds to catch up to international…

China Better known for its panda sanctuary and spicy local cuisine, Chengdu could be the first Chinese city to offer mutual health insurance. Eric Bouteiller examines French firm VYV’s first steps into China and the potential impact of mutual insurance – whereby the insurance company is owned entirely by its policyholders…

China Ingrid Zhang, president of Novartis Pharmaceuticals China, shares the transformation of Novartis China in the past two years in line with the global Novartis vision; their aspiration to become a powerhouse for bringing innovative products to China and to develop talents; their commitment to working with various stakeholders to promote…

China Robert Braithwaite, CEO and co-founder at LUQA Pharmaceuticals, a China-based specialty pharmaceutical company focusing on dermatology and aesthetics, shares his inspiration for establishing the company in 2010 to bring ‘hidden gems’ from the global industry to the China market, their focus on establishing a strong expertise in skin and building…

China TJ Deng, GM China and BioDuro Discovery; and Ian Wisenberg, CFO of BioDuro, share the strategic rationale behind Advent International’s 2019 investment into the company; the focus of BioDuro 4.0 on growth, particularly in the US and Chinese markets; the differentiated and value-added services BioDuro can offer clients; and their…

China Dr Chengbin Wu, founder and CEO of EpimAb Biotherapeutics, introduces their exciting and proprietary bispecific antibody-generating platform, Fabs-In-Tandem Immunoglobulin (FIT-Ig®) and its ability to discover and generate novel and differentiated bispecific antibodies to meet unmet medical needs in China; shares the progress of their first program, EMB01, a EGFR-cMet bispecific…

China Amidst the sea of Big Pharma executives jumping ship to start highly regarded and attention-grabbing biotech companies, bolstered by the huge influx of capital, the opening of stock exchanges in first Hong Kong and subsequently Shanghai to pre-profit biotech companies that meet certain criteria, as well as the reformation and…